Formulation, Characterization and Evaluation against SH-SY5Y Cells of New Tacrine and Tacrine-MAP Loaded with Lipid Nanoparticles

Tacrine (TAC) was the first FDA approved drug for the treatment of Alzheimer’s disease, resulting in increased memory and enhanced cognitive symptoms in patients. However, long-term therapy presents poor patient compliance associated with undesired side effects such as nausea, vomiting and hepatoxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Sara, Marto, Joana, Gonçalves, Lídia, Almeida, António J., Vale, Nuno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589787/
https://www.ncbi.nlm.nih.gov/pubmed/33096919
http://dx.doi.org/10.3390/nano10102089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589787/
https://www.ncbi.nlm.nih.gov/pubmed/33096919
http://dx.doi.org/10.3390/nano10102089

Ejemplares similares